This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

When the Fed Responds, These Stocks Will Correct

My biggest caveat here is that all this great news is already priced into Pfizer's share price, which is slightly below its $23.80, 52-week high established intra-day on Friday.

With the price at current levels it lowers the dividend yield to below 4%. It was less than a year ago that investors were chasing Pfizer's 5.25% yield when the price was down below $16.70. Today's share price means the stock has climbed 40% in less than 12 months. Watch out below!

The same could be said for other Big Pharma stocks including Bristol-Myers Squibb (BMY) and Abbott Laboratories (ABT), whose price has risen above $64 while the yield-to-price is down around 3.2%.

That's a heck of a better yield than a seven-year Treasury, which yields only 0.90%, or the 10-year Treasury currently at a historically low 1.41%.

Yet, at some point (most likely after the next helping of MQE) a return of what the Wall Street media has called the "risk-on trade" will surge and a rotation out of the historically higher yielding stocks like REITs and drug companies will happen in a New York minute.

If you have the foresight and guts to sell at these high levels, you'll probably have the chance to buy them back after the correction in this "risk off" stocks runs its course. You'll then have a higher yield-to-price dividend and the chance to catch the next run-up in the mortgage REITs and the big drug stocks.

At the time of publication the author was long NLY.

This article is commentary by an independent contributor, separate from TheStreet's regular news coverage.

Jim Cramer and Stephanie Link actively manage a real money portfolio for his charitable trust- enjoy advance notice of every trade, full access to the portfolio, and deep coverage of the latest economic events and market movements.
3 of 3

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
HTS $16.08 0.82%
NLY $10.62 1.60%
PFE $33.56 0.48%
AAPL $93.21 -0.44%
FB $117.80 -0.22%


Chart of I:DJI
DOW 17,660.71 +9.45 0.05%
S&P 500 2,050.63 -0.49 -0.02%
NASDAQ 4,717.0940 -8.5450 -0.18%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs